Bifidobacterium breve

Eamonn Martin Quigley

doi:10.1016/B978-0-12-804024-9.00015-X

Bifidobacterium breve

Eamonn Martin Quigley

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.

Original language	English (US)
Title of host publication	The Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publication	Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis
Publisher	Elsevier
Pages	135-137
Number of pages	3
ISBN (Electronic)	9780128040621
ISBN (Print)	9780128040249
DOIs	https://doi.org/10.1016/B978-0-12-804024-9.00015-X
State	Published - Jan 1 2017

Keywords

Allergy
B632
BB536
BR-03
Bifidobacterium breve strains BBG-001
C-50 and Yakult
CNCM I-4035
Immunomodulation
M-16V
Necrotizing enterocolitis

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/B978-0-12-804024-9.00015-X

Cite this

@inbook{4c6ba5ee9252402997f4c8689f7c56b4,

title = "Bifidobacterium breve",

abstract = "Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.",

keywords = "Allergy, B632, BB536, BR-03, Bifidobacterium breve strains BBG-001, C-50 and Yakult, CNCM I-4035, Immunomodulation, M-16V, Necrotizing enterocolitis",

author = "Quigley, {Eamonn Martin}",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-804024-9.00015-X",

language = "English (US)",

isbn = "9780128040249",

pages = "135--137",

booktitle = "The Microbiota in Gastrointestinal Pathophysiology",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Bifidobacterium breve

AU - Quigley, Eamonn Martin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.

AB - Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.

KW - Allergy

KW - B632

KW - BB536

KW - BR-03

KW - Bifidobacterium breve strains BBG-001

KW - C-50 and Yakult

KW - CNCM I-4035

KW - Immunomodulation

KW - M-16V

KW - Necrotizing enterocolitis

UR - http://www.scopus.com/inward/record.url?scp=85027365521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027365521&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804024-9.00015-X

DO - 10.1016/B978-0-12-804024-9.00015-X

M3 - Chapter

SN - 9780128040249

SP - 135

EP - 137

BT - The Microbiota in Gastrointestinal Pathophysiology

PB - Elsevier

ER -

Bifidobacterium breve

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this